Secoisolariciresinol diglucoside

Secoisolariciresinol diglucoside (SDG) is a plant lignan found primarily in flaxseed that acts as a precursor to the mammalian lignans enterodiol and enterolactone. These metabolites exhibit phytoestrogenic activity and provide antioxidant protection against oxidative stress and liver peroxidation damage.

Origin & History

Secoisolariciresinol diglucoside (SDG) is a plant lignan found predominantly in flaxseed, but also in sunflower, sesame, and pumpkin seeds. It was first isolated in 1956 and is produced enzymatically from secoisolariciresinol in flaxseeds.

Historical & Cultural Context

The research dossier does not include information on the traditional or historical use of SDG. Its applications seem to be more contemporary, focusing on its biochemical properties and potential health benefits.

Health Benefits

• Antihyperglycemic effects: SDG at 25 mg/kg body weight showed potential in animal models [1].
• Antioxidant properties: Functions as a phytoestrogen preventing liver peroxidation damage [1].
• Precursor to mammalian lignans: Converts to enterodiol and enterolactone in the colon, which have health benefits [7].
• Potential cardiovascular benefits: Derived from its antioxidant capacity, though specific human studies are lacking [4].
• Supports hormonal balance: As a phytoestrogen, may help modulate estrogen levels, though direct evidence is minimal [4].

How It Works

SDG is converted by colonic bacteria into the mammalian lignans enterodiol and enterolactone, which bind to estrogen receptors and exert phytoestrogenic effects. These metabolites scavenge free radicals and inhibit lipid peroxidation through their phenolic hydroxyl groups. The compounds also modulate glucose metabolism pathways, contributing to their antihyperglycemic properties.

Scientific Research

The research dossier does not provide specific human clinical trials or meta-analyses with PubMed PMIDs. The references to antihyperglycemic effects and the role of SDG as a precursor to mammalian lignans are based on preliminary findings from animal studies and biochemical analyses.

Clinical Summary

Current evidence for SDG comes primarily from animal studies rather than human clinical trials. In animal models, SDG at 25 mg/kg body weight demonstrated antihyperglycemic effects and liver protection against oxidative damage. The compound's conversion to enterodiol and enterolactone has been documented in human studies, though specific health outcomes from SDG supplementation require more extensive clinical research. Evidence strength remains preliminary due to limited human trials.

Nutritional Profile

Secoisolariciresinol diglucoside (SDG) is a pure polyphenolic lignan compound, not a whole food, so traditional macronutrient/micronutrient profiles do not apply. Key compositional and bioactive data: SDG is a diglucoside ester of secoisolariciresinol (SECO), with molecular weight approximately 686.7 g/mol. It is the predominant lignan in flaxseed, found at concentrations of 6–37 mg/g of defatted flaxseed meal, and is typically isolated as part of a lignan-rich fraction (SDG complex) comprising approximately 40–60% SDG by weight alongside other phenolic compounds including cinnamic acid glucosides (ferulic acid glucoside, p-coumaric acid glucoside) and 3-hydroxy-3-methyl glutaric acid. As an isolated compound, it contains no meaningful protein, fat, or carbohydrate nutritional content. Bioactive profile: SDG serves as a direct precursor to mammalian lignans enterodiol (ED) and enterolactone (EL) via colonic bacterial metabolism; conversion efficiency varies by gut microbiome composition. SDG itself exhibits antioxidant activity with an oxygen radical absorbance capacity (ORAC) measurable in vitro. Bioavailability: oral bioavailability of SDG is moderate; colonic bacteria cleave the glucoside bonds releasing SECO, which is further converted to ED and EL. Peak plasma enterolactone levels typically appear 8–10 hours post-ingestion. Fat co-ingestion may enhance absorption. Typical experimental doses used in animal studies: 25 mg/kg body weight. Human supplementation studies have used SDG complex doses of 300–600 mg/day.

Preparation & Dosage

Animal studies suggest an effective dose of 25 mg/kg body weight for antihyperglycemic effects. Human dosage guidelines are not available from the provided research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Flaxseed oil, Omega-3 fatty acids, Vitamin E, Curcumin, Resveratrol

Safety & Interactions

SDG safety profile appears favorable based on its natural occurrence in flaxseed, though comprehensive safety data is limited. Due to its phytoestrogenic activity through enterodiol and enterolactone metabolites, individuals with hormone-sensitive conditions should exercise caution. Potential interactions with anticoagulant medications may occur due to flaxseed's fiber content affecting drug absorption. Pregnancy and breastfeeding safety has not been established through clinical studies.